Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBIT Margin (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed EBIT Margin for 9 consecutive years, with 2380.08% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin changed N/A year-over-year to 2380.08%; the TTM value through Mar 2026 reached 479811.76%, changed N/A, while the annual FY2025 figure was 1407.52%, N/A changed from the prior year.
  • EBIT Margin hit 2380.08% in Q1 2026 for Crescent Biopharma, down from 1959.93% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1959.93% in Q2 2025 and bottomed at 17804.21% in Q2 2022.
  • Average EBIT Margin over 3 years is 6074.79%, with a median of 2380.08% recorded in 2026.
  • On a YoY basis, EBIT Margin climbed as much as 1012619720bps in 2022 and fell as far as 1012619720bps in 2022.
  • Crescent Biopharma's EBIT Margin stood at 17804.21% in 2022, then soared by 111bps to 1959.93% in 2025, then crashed by -221bps to 2380.08% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 2380.08%, 1959.93%, and 17804.21% for Q1 2026, Q2 2025, and Q2 2022 respectively.